Tonix Pharmaceuticals Holding Corp.
Release data from non-human primate studies involving challenge with SARS-CoV-2
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expects to release data from non-human primate studies involving challenge with SARS-CoV-2 in the first quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company reported positive efficacy data from non-human primate challenge studies using live SARS-CoV-2 in the first quarter of 2021, meeting its stated commitment.
-
A Tonix Pharmaceuticals Holding Corp. 10-Q filed 2021-05-10
“We reported positive immune response data in non-human primates in the fourth quarter of 2020 and reported positive efficacy data from animal challenge studies using live SARS-CoV-2 in the first quarter of 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Release
- Deliverable
- Non-human primate study data for TNX-1800
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tonix Pharmaceuticals Holding Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-TNXP-023270 · Corrections policy